Severity and risk of<scp>COVID</scp>‐19 in cancer patients: An evidence‐based learning

Sharma, Akanksha; Malviya, Rishabha; Kumar, Vinod; Gupta, Rashmi; Awasthi, Rajendra

doi:10.1111/dth.13778

Cited by 12 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported a higher risk of COVID‐19 infection and induced complications in patients with cancer. 4 In response to both this higher vulnerability of patients with cancer to COVID‐19 and the lockdown measures, guidelines were issued to adjust oncologic care during the COVID‐19 pandemic. 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 This led to frequent delays and disruptions in cancer health care.…”

Section: Introductionmentioning

confidence: 99%

Post‐traumatic stress symptomatology and adjustment of medical oncology practice during the COVID‐19 pandemic among adult patients with cancer in a day care hospital

Joly

Rigal²,

Guittet

et al. 2021

Cancer

View full text Add to dashboard Cite

BACKGROUND:The COVID-19 pandemic may induce post-traumatic stress disorder (PTSD) symptoms among patients with cancer, who also face adaptations to their treatment. The authors assessed the occurrence of PTSD symptoms, investigated pandemic-induced adjustments in medical oncology practice in patients with cancer, and explored risk factors for PTSD and the association between PTSD symptoms, insomnia, and quality of life (QoL). METHODS: This prospective French study was conducted in patients with solid/hematologic tumors who were receiving medical treatment in the day care departments of 2 cancer centers during the lockdown. Adjustments to medical oncology practice were collected from medical records. PTSD (measured using the Impact of Event Scale-Revised), insomnia (measured using the Insomnia Severity Index), QoL (measured using the Functional Assessment of Cancer Therapy-General instrument), and cognitive complaints (measured using the Functional Assessment of Cancer Therapy-Cognitive Function instrument) were collected through validated questionnaires. RESULTS: Clinical data and questionnaires were available for 734 and 576 patients, respectively. The median patient age was 64 years, and 69% of patients were women. Twenty-one percent of patients had PTSD. Twenty-seven percent (95% CI, 23%-30%) had an adjustment in their medical oncology program, including adjournments (29%), treatment interruptions (16%), modified treatment plans (27%), or adapted monitoring (27%). Women and patients experiencing an adjustment in oncology practice had a higher odds of PTSD (odds ratio= 2.10 [95% CI, 1.07-4.14] and 1.65 [95% CI, 1.03-2.63]; P < .05). PTSD symptoms were correlated with worse scores for QoL, cognition, and insomnia. CONCLUSIONS: Twenty-one percent of patients with cancer experienced PTSD symptoms associated with poor QoL during the first COVID-19-induced lockdown. Medical oncology practice was adjusted in approximately one-quarter of patients and was associated with the occurrence of PTSD symptoms. Psychosocial support should be offered in cancer centers to promote emotional resilience and avoid PTSD symptoms in patients. Cancer 2021;0:1-10.

show abstract

Section: Introductionmentioning

confidence: 99%

Post‐traumatic stress symptomatology and adjustment of medical oncology practice during the COVID‐19 pandemic among adult patients with cancer in a day care hospital

Joly

Rigal²,

Guittet

et al. 2021

Cancer

View full text Add to dashboard Cite

show abstract

“…[14][15][16] Oncologists hold different notions and continue to receive mixed messages regarding whether cancer patients should receive anti-tumor treatments as usual. [17][18][19] In light of this, a systematic review is needed to summarize the best available evidence of the impact of anti-cancer therapy in cancer patients with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Wang

Huang

2020

OncoImmunology

View full text Add to dashboard Cite

Background: This study was designed to investigate whether COVID-19 patients with recently received immunotherapy or other anti-cancer treatments had more severe symptoms and higher mortality. Methods: A literature search was performed using the electronic platforms to obtain relevant research studies published up to June 28, 2020. Odds ratio (OR) and 95% confidence intervals (CI) of research endpoints in each study were calculated and merged. Statistical analyses were performed with Stata 12.0 (Stata Corp LP, College Station, TX). Results: A total of 17 studies comprising 3581 cancer patients with COVID-19 were included in this metaanalysis. SARS-CoV-2-infected cancer patients who recently received anti-cancer treatment did not observe a higher risk of exacerbation and mortality (All p-value >0.05). We also found that surgery, targeted therapy, chemotherapy, immunotherapy, and radiotherapy were not associated with increased risk of exacerbation and mortality (All p-value >0.05). Chemotherapy within 28 d increased the risk of death events (OR 1.45, 95% CI 1.10-1.91, P = .008, p-value = 0.015 for test of interaction), and immunotherapy within 90 d increased the risk of exacerbation (OR 2.53,95%1.30-4.91, P = .006, p-value = 0.170 for test of interaction). Conclusion: Cancer patients recently under anti-cancer treatment before diagnosed with COVID-19, including surgery, targeted therapy, immunotherapy, and radiotherapy, were not associated with increased risk of exacerbation and mortality. Chemotherapy within 28 d increased the risk of mortality, and chemotherapy was not associated with increased risk of severe COVID-19. The role of anti-cancer therapy in cancer patients with COVID-19 still needs further exploration, especially chemotherapy and immunotherapy.

show abstract

“…According to Lee et al cancer patients are twice more likely to contract the infection than the normal population (Lee et al, 2020 ). Patients who received chemotherapy or surgery within the 30 days before the COVID-19 pandemic have more risk of infection than the patients who had not undergone chemotherapy or surgery (Sharma et al, 2020 ). According to an analysis of Italian patients published in March, 20% of those who died from COVID-19 in the country had active cancer (Liang et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Renal Carcinoma Is Associated With Increased Risk of Coronavirus Infections

Tripathi

Deshmukh

Creighton

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: The current COVID-19 pandemic has affected most severely people with old age, or with comorbidities like hypertension, diabetes mellitus, and cancer. Cancer patients are twice more likely to contract the disease because of the malignancy or treatment-related immunosuppression; hence identification of the vulnerable population among these patients is essential.Method: We took a bioinformatics approach to analyze the gene and protein expression data of these coronavirus receptors (DPP4, ANPEP, ENPEP, TMPRSS2) in human normal and cancer tissues of multiple organs including the brain, liver, kidney, heart, lung, skin, GI tract, pancreas, endocrine tissues, and the reproductive organs. RNA-Seq data from The Cancer Genome Atlas (TCGA) and GTeX databases were used for extensive profiling analysis of these receptors across 9,736 tumors and 8,587 normal tissues comparing coronavirus receptors. Protein expression from immunohistochemistry data was assessed from The Human Protein Atlas database including 144 samples, corresponding to 48 different normal human tissue types, and 432 tumor samples from 216 different cancer patients. The correlations between immune cell infiltration, chemokine, and cytokines were investigated via Tumor Immune Estimation Resource (TIMER) and TCGA.Result: We found that among all, renal tumor and normal tissues exhibited increased levels of ACE2, DPP4, ANPEP, and ENPEP. Our results revealed that TMPRSS2 may not be the co-receptor for coronavirus infection in renal carcinoma patients. The other receptors DPP4, ANPEP, and ENPEP may act as the compensatory receptor proteins to help ACE2. The receptors' expression levels were variable in different tumor stage, molecular, and immune subtypes of renal carcinoma. Intriguingly, in clear cell renal cell carcinomas, coronavirus receptors were associated with high immune infiltration, markers of immunosuppression, and T cell exhaustion.Conclusion: Our study indicates that CoV receptors may play an important role in modulating the immune infiltrate and hence cellular immunity in renal carcinoma. As our current knowledge of pathogenic mechanisms will improve, it may help us in designing focused therapeutic approaches.

show abstract

Severity and risk ofCOVID‐19 in cancer patients: An evidence‐based learning

Cited by 12 publications

References 13 publications

Post‐traumatic stress symptomatology and adjustment of medical oncology practice during the COVID‐19 pandemic among adult patients with cancer in a day care hospital

Post‐traumatic stress symptomatology and adjustment of medical oncology practice during the COVID‐19 pandemic among adult patients with cancer in a day care hospital

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Renal Carcinoma Is Associated With Increased Risk of Coronavirus Infections

Contact Info

Product

Resources

About